Delcath Systems, Inc. (Delcath) is a development-stage, specialty pharmaceutical and medical device company, focused on oncology, initially cancers in the liver. Delcath focuses on the development and clinical study of the Delcath chemosaturation system. The Delcath chemosaturation system allows the administration of concentrated regional chemotherapy by isolating the circulatory system of the targeted organ. Once the organ is isolated, the Delcath chemosaturation system delivers doses of chemotherapeutic agents directly to the liver. The Delcath chemosaturation system involves a series of three catheter insertions, each of which is placed percutaneously through interventional radiology techniques. The procedure is minimally invasive and repeatable allowing for multiple courses of treatment with chemotherapeutic drugs. On April 13, 2011, it received Conformite Europeenne (CE) mark approval for the Delcath Hepatic CHEMOSAT Delivery System (CHEMOSAT System).